Palisade Bio (PALI) Notes Payables (2010 - 2013)

Palisade Bio's (PALI) quarterly Notes Payables came in at $1.4 million in Q4 2013, up 8.05% on a QoQ basis from $1.3 million in Q3 2013.

Palisade Bio (PALI) Notes Payables (2010 - 2013) Analysis & Trends

Palisade Bio (PALI) has 2 years of Notes Payables data on file, last reported at $1.4 million in Q4 2013.

On a quarterly basis, Notes Payables changed N/A year-over-year to $1.4 million in Q4 2013; TTM through Dec 2013 was $1.4 million, a N/A change from a year earlier, with the FY2013 full-year figure at $1.4 million, changed N/A from the prior year.
Notes Payables for Q4 2013 stood at $1.4 million, up from $1.3 million in the prior quarter.
Over the last five years, Notes Payables for PALI reached as high as $1.4 million in Q4 2013 and fell as low as $445680.0 in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Palisade Bio	985.76	-132.63 Mn	-

Download Data